The Alpha-1 Project and Poliwogg Form Partnership To Find Therapies, Cures for Alpha-1 Antitrypsin Deficiency
The Alpha-1 Project, a venture philanthropy company created to speed development of new therapies and potential cures for lung and liver diseases caused by Alpha-1 Antitrypsin Deficiency, announced a partnership today with Poliwogg, an innovative financial firm transforming healthcare investing.
San Francisco, Calif. (PRWEB) January 13, 2014
The Alpha-1 Project, a venture philanthropy company created to speed development of new therapies and potential cures for lung and liver diseases caused by Alpha-1 Antitrypsin Deficiency, announced a partnership today with Poliwogg, an innovative financial firm transforming healthcare investing. The Alpha-1 Project is a wholly owned subsidiary of the Alpha-1 Foundation.
“We continue to incorporate creative and useful tools in our armamentarium to help finance and support our industry partners,” said Jean-Marc Quach, Executive Director of The Alpha-1 Project.
“Poliwogg is an ideal partner for the Alpha-1 Foundation and its venture philanthropy arm, The Alpha-1 Project,” said John Walsh, President and CEO of the Alpha-1 Foundation and a Board member of The Alpha-1 Project. “We must explore innovative ways to fund research in order to find the new therapies and ultimately the cures we need for lung and liver diseases caused by Alpha-1 Antitrypsin Deficiency,” he added.
“Foundations have an enormously important role to play in identifying companies with promising approaches to improving the quality of life for people affected by debilitating and deadly diseases,” said Greg Simon, CEO of Poliwogg. “The Alpha-1 Project and the Alpha-1 Foundation are leaders in bringing scientific and business diligence to bear in the interests of people with Alpha-1. Poliwogg is proud to work with the Alpha-1 Foundation and the Alpha-1 Project as part of our mission to help fund promising companies by making health investments more accessible to millions of people.”
About Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic condition – passed on from parents to their children through genes. Alpha-1 may result in serious lung and/or liver disease. Alpha-1 is the most common known genetic cause of COPD. There are at least 100,000 people with Alpha-1 in the United States.
About The Alpha-1 Project
The Alpha-1 Project (TAP) is a wholly-owned for profit subsidiary of the Alpha-1 Foundation singularly focused on providing critical funding and advice to speed the commercialization of therapies for the elimination of Chronic Obstructive Pulmonary Disease (COPD) and liver disease caused by Alpha-1.
About the Alpha-1 Foundation
The Alpha-1 Foundation is a not-for-profit Florida corporation founded in 1995 by three individuals with Alpha-1. The Foundation is dedicated to providing the leadership and resources that will result in increased research, improved health, worldwide detection, and a cure for Alpha-1 Antitrypsin Deficiency.
Poliwogg is an innovative financial firm transforming healthcare investing. We provide pathways for accredited investors to invest in early stage companies in health and life sciences, structure indexes that quantify the impact of public companies in health, and are launching sector specific publicly registered venture funds focused by health vertical. Our mission is to transform health from a cost to an asset class. For more information, visit http://www.poliwogg.com. Follow Poliwogg on Twitter @poliwoggpond, and on LinkedIn.
Fastlane Communications for Poliwogg
Executive Director, The Alpha-1 Project
Jeffrey Feldman, Director, Poliwogg Board
Private investment marketing and other broker-dealer services are currently offered through a partnership with SDDCO Brokerage Advisors, LLC, Member FINRA/SIPC (“SDDCO-BA”). All such services offered by Poliwogg-associated persons are done so in their capacities as registered representatives of SDDCO-BA. Poliwogg and its affiliates are independent and unaffiliated with SDDCO-BA.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/01/prweb11483584.htm